I. Introduction
Rheumatoid arthritis (RA) is an autoimmune disease of the musculoskeletal system that ischaracterized by inflammation and destruction of joints, associated with considerable morbidity and diminished quality of life [1] and imposes a substantial economic burden to patients and society [2] . RA affects approximately 1% of the worldwide population [3] . The treatment of RA involves NSAIDs, methotrexate and other DMARDs. Those patients failing to respond to these medication invariably require other biologic agents such as infliximab, etanercept, Yet there are significant challenges with the current lot of drugs that has fueled the search for better molecules with robust efficacy and acceptable safety. One of the most recent drugs to receive marketing approval by the office of the Drug Controller General of India for the treatment of rheumatoid arthritis is tofacitinib, which was approved in April 2016. We have attempted to review tofacitinibwhich includes the mechanism of action, efficacy, safety and pharmacokinetics of the drug.
II. Mechanism of Action
Tofacitinib (CP-690,550) is a Janus kinase inhibitor that is a targeted immunomodulator and has disease-modifying potential in Rheumatoid arthritis [4, 5] Optimizationof a pyrrolopyrimidine-based series of inhibitors represented by CP-352,664 led to identification of tofacitinib. [6 ] The drug inhibits signaling through JAK1 and JAK3 /STATpathway with selectively reduced cellular potency of JAK2. [7] Tofacitinib inhibits signaling by heterodimeric receptors bound among JAK1 and JAK3 with functional selectivity of receptors that signal via JAK2, which blocks signaling for several cytokines and interleukins. Autoimmune diseases can be induced by CD4 + T cells that produce IFN-γ (Th1 cells), IL-17 (Th17 cells) [8] .Keisuke et al has suggested that tofacitinib directly suppressed the production of IL-17 and IFN-γ and proliferation of CD4 + T cells. However, the precise mechanisms by which JAK inhibition improves inflammatory immune responses remain unclear.
III. Efficacy
The clinical efficacy and safety of tofacitinib was tested in five Phase III, randomized, double blind, placebo controlled studies ORAL Step(A3921044; NCT00847613), ORAL Solo (A3921045;NCT00814307), ORAL Sync (A3921046; NCT00856544) and ORAL Standard (A3921064; NCT00853385).The efficacy parameters assessed to test the efficacy of Tofacitinib includes American College of Rheumatology (ACR) 20/50/70 response rates; the percentage of patients with a Disease Activity Score for 28-joint counts based on the erythrocyte sedimentation rate (DAS28-4[ESR]) of less than 2.6 (with scores ranging from 0 to 9.4 and higher scores indicating more disease activity); Health Assessment Questionnaire-Disability Index(HAQ-DI),which range from 0 to 3, with higher scores indicating greater disability.
The ORALSolo and ORAL Sync study included patients who have inadequate response to DMARD, while the ORALScan and ORALStandard study had patients with poor response to methotrexate and the ORALStep study included patients who had failed to respond to TNF alpha inhibitors. [9] .Tofacitinib showed favorable ACR-20/50/70 response rate and improvement in HAQ-DI scorewhen compared to placebo for all the Phase III studies. Though there was significant heterogeneity among the studies stated,the odds of tofacitinib treated patients who achieved the efficacy criteria was significantly higher in the placebo group. The significant 
IV. Pharmacokinetics
Greater clinical response was reported for tofacitinib 5mg and 10mg twice daily. When a single 50-mg (14)C-labeled tofacitinib dose prescribed to the subjects, the mean (standard deviation) total percentage of administered radioactive dose recovered was 93.9% (±3.6), with 80.1% (±3.6) in the urine (28.8% parent), and 13.8% (±1.9) in feces (0.9% parent). The drug was absorbed, with plasma concentrations and total radioactivity peaking at around 1 hour after oral administration.Tofacitinib is highly protein bound and metabolized by CYP3A4, which accounts for 70% of the hepatic clearance and remaining 30% are renally excreted. The preponderant metabolic pathways of tofacitinib includes oxidation of the pyrrolopyrimidine and piperidine rings, oxidation of the piperidine ring side-chain, N-demethylation and glucuronidation. The drug has a half life of 3.5 hrs. [12] 
V. Safety
Patients on tofacitinib are unsurprisingly at a greater risk of infections and this has to be borne in mind before prescribing tofacitinib. Herpes zoster, opportunistic infections and tuberculosis were the serious infections that were seen at a higher incidence with tofacitinib. The most common treatment-related infections were bronchitis (1.6%), nasopharyngitis (1.4%), upper respiratory tract infection (1.4%), urinary tract infection (1.4%), and oral herpes virus infection (1.4%). [11, 13] The common laboratory changes observed after treatment of tofacitinib includes sporadic increases in transaminase levels, increases in cholesterol and serum creatinine levels, and decrease in neutrophil and hemoglobin levels [11] Tofacitinib treated patients had a low incidence of CV events in phase III trials, despite their elevation in cholesterol level. [14] For the patients receiving tofacitinib the most frequently reported adverse events that were mild in severity include headache, diarrhea, nausea, urinary tract infection, upper respiratory tract infection, nasopharyngitis, influenza and cough.
VI. Current Status
Tofacitinib is the first oral JAK inhibitor developed for the treatment of RA in the late 2012.Some of the issues that need further clarity with tofacitinib includes efficacy of the drug as monotherapy, head-toheadcomparison with other BDMARD(biologic-D-MARD) such as adalimumab,etanercept,certolizumab and tocilizumab. Most biologic agents need to be administered parenterally either as subcutaneous as in etanercept, adalimumab or intravenous as in certolizumab, rituximab and infliximab. In contrast, tofacitinib has a distinct advantage of oral administration which would improve the patient adherence.
VII. Conclusion
Tofacitinib is a pioneering oral Janus kinase inhibitor that has recently entered the burgeoning market for the treatment of rheumatoid arthritis. In the active RA patients, for whom the response was inadequate with respect to DMARDs, the addition of tofacitinibdemonstrated significant efficacy over placebo. Patients on tofacitinib are at a greater predilection to develop infections owing to the drug's property to interfere with the immunologic defenses. Although the pharmacological options for the treatment of rheumatoid arthritis is flooded with a gamut of options, there is a definite need for cheaper, effective medication with reasonable safety margin. Tofacitinib while not clearing the cost hurdle does appear to have value in minimizing the symptoms of the disease. Post marketing studies and studies comparing the drug with other biologic agents would help us understand the drug better in the days ahead to see if this could carve a niche for itself in the pharmacotherapy of rheumatoid arthritis.
